ZAI LAB LIMITED - AMERICAN DEPOSITARY SHARES

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

05 مايو 2022 11:54:58 بحسب Nasdaq GlobeNewswire

Zai Lab and Turning Point Therapeutics Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study

28 أبريل 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Engagement of KPMG LLP, a U.S. Auditor, as the Company’s Independent Registered Public Accounting Firm

21 أبريل 2022 07:30:01 بحسب Nasdaq GlobeNewswire

Zai Lab to Announce First Quarter 2022 Financial Results on May 10, 2022

20 أبريل 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Plants a Tree for Every Employee on Earth Day 2022

19 أبريل 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Zai Lab to Present New Oncology Research at 2022 AACR Annual Meeting

06 أبريل 2022 08:01:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Change to Virtual Extraordinary General Meeting of Shareholders to be Held on March 28, 2022

23 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Presents Positive Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) at Society of Gynecologic Oncology Meeting

20 مارس 2022 20:00:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces the Appointment of Josh Smiley as Chief Operating Officer

15 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021

01 مارس 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in China

17 فبراير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022

15 فبراير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Upcoming Presentation at February Investor Conference

07 فبراير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer

12 يناير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

06 يناير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Upcoming Presentations at January Investor Conferences

29 ديسمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

22 ديسمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

17 ديسمبر 2021 18:09:04 بحسب Nasdaq GlobeNewswire

China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

16 ديسمبر 2021 04:43:33 بحسب Nasdaq GlobeNewswire

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer

03 ديسمبر 2021 07:30:00 بحسب Nasdaq GlobeNewswire